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Summary We have investigated the effectiveness of three different F(ab'y)2 bispecific antibodies (BsAb) for
delivering the ribosome inactivating protein (RIP) saporin via the CD7 or CD38 cell surface molecules to the
human T-ALL cell lines HSB-2 and HPB-ALL. Inhibition of 3H-leucine uptake by target cells was used as the
parameter of cellular cytotoxicity. Used singly against HSB-2 cells in the presence of varied concentrations of
saporin, an anti-CD7 BsAb, (HB2 x DB7-18) and an anti-CD38 BsAb (OKT1O x RabSap), gave 435- and
286-fold increases in saporin toxicity, respectively. For HPB-ALL cells the anti-CD7 BsAb performed poorly
giving only an eight-fold increase in toxicity whilst on the same cell line the anti-CD38 BsAb was highly potent
giving an 80,000-fold increase in saporin toxicity.
A combination of both BsAb used together against HSB-2 cells was ten times more effective, than the best
single BsAb HB2 x DB7- 18 used alone. Kinetic studies conducted with HSB-2 cells revealed that the BsAb
combination also gave an increased rate of protein synthesis inactivation in comparison to either BsAb used
alone. These investigations clearly demonstrate a synergistic action when both BsAb are used in combination
to target saporin against CD7 and CD38 expressed on the surface of the HSB-2 cell line.
The principle of using monoclonal antibodies for delivering
drugs or toxins to distinct molecular structures expressed on
the surface of unwanted tumour cells is an attractive one and
has come under intense investigation in recent years (Hertler
& Frankel, 1989). Theoretically, such a targeted approach to
cancer therapy could offer a major advance in the selective
elimination of tumour cells, improving the effective tumour
cell kill rate whilst reducing the toxicity of treatment for
non-target tissues overall. In practice many problems still
need to be overcome before immunotoxin or antibody-drug
conjugate-type therapies can be truly effective in vivo (Fran-
kel et al., 1986).
One potential limitation to the success of any targeted
approach to therapy would be the heterogeneity of target
antigen expression within a population of tumour cells. It
follows that if a small number of cells within the tumour
were negative for a single target antigen or, expressed the
antigen only very weakly, then these cells would escape des-
truction due to a failure of antibody-mediated delivery of the
cytotoxic agent to those particular cells. A possible means of
overcoming this potential problem would be to target the
cytotoxic agent against more than one cell surface target
molecule, in the expectation that target tumour cells which
were multiple antigen negative would occur with a lower
frequency than single antigen negative target cells. This
strategy would not only improve the likelihood of delivering
the cytotoxic agent to all cells within the tumour, but would
also ensure delivery of greater amounts of the agent to those
cells that express all the target antigens. To investigate this
possibility we have studied the cytotoxic efficacy of three
different bispecific antibodies (BsAb) used singly or in com-
bination, for delivering the ribosome inactivating protein
(RIP) saporin to two different human T-ALL cell lines using
CD7 and CD38 as the cellular target molecules.
Materials and methods
Human acute T-cell leukaemia cell lines
The T-ALL cell lines HSB-2 and HPB-ALL were used in
these studies. Both cell lines were maintained in RPMI 1640
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medium containing 10% foetal calf serum (Gibco), and sup-
plemented with 1 mmol glutamine, 1 mmol sodium pyruvate,
100IUm1'- benzyl penicillin and 100 ggml-l streptomycin
sulphate. Cells were maintained continuously in the logarith-
mic phase of growth by passage at regular intervals.
Saporin
The ribosome inactivating protein (RIP) saporin was purified
from the seeds of Saponaria officinalis as described previously
(Stirpe et al., 1983).
Antibodies
Ascitic fluids containing the anti-saporin mouse monoclonal
antibody DB7-18, the anti-CD7 antibody HB2 and the anti-
CD38 antibody OKT1O, all murine antibodies of the IgGI
subclass were produced by injecting 1 x 107 of the appropri-
ate hybridoma cell line into the peritoneal cavity of pristane
primed BALB/c mice.
Polyclonal antisera reacting with saporin were raised in
half lop rabbits using standard immunisation protocols
(Glennie et al., 1987).
The 7S IgG fractions of ascitic fluids and polyclonal
antisera were isolated by precipitation with 2 M ammonium
sulphate followed by ion exchange chromatography on Tris-
acryl-M-DEAE (Elliott et al., 1987). F(ab')2 fragments from
both monoclonal and polyclonal IgG were prepared by
limited proteolysis with pepsin at pH 4.2 as described pre-
viously (Glennie et al., 1987).
Construction ofbispecific F(ab')2 antibodies
Heterodimeric F(ab'y)2 molecules containing two different
mouse Fab' fragments or a mixture of mouse and rabbit Fab'
fragments were constructed as described by Glennie et al.
(1987). Briefly, F(ab'y)2 fragments of the required antibody
were reduced to obtain Fab' fragments with hinge region SH
groups, Fab'(SH). The SH groups on one of the Fab' (SH)
species were then fully alkylated with excess 0-phenylene-
dimaleimide to provide free maleimide groups. The two
preparations, Fab'(mal) and Fab'(SH) were then combined
under conditions which allowed cross linking of the malei-
mide and SH groups and avoided reoxidation of the SH
groups. The final products were reduced and alkylated to
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remove any minor untoward products which may have
formed by oxidation or disulphide exchange and the final
mixture fractionated according to size by chromatography on
Ultragel AcA44 (LKB-Produkter AB, Bromma, Sweden).
Three different F(ab'y)2 BsAb were constructed in this way
the details of which are given in Table 1.
Analysis ofcell surface expression ofCD7 and CD38 byflow
cytometry
Cells were analysed for surface expression of CD7 and CD38
by flow cytometry. Cells were incubated for 1 h at room
temperature with a saturating concentration of HB2 (anti-
CD7) or OKT10 (anti-CD38) antibody in the presence of
0.01% sodium azide. Following the first incubation cells were
washed twice and incubated with a 1:20 dilution of fluor-
escein isothiocyanate conjugated F(ab')2 fragnents of a rab-
bit anti-mouse immunoglobulins antisera (Sigma Chemical
Co., Poole, UK). Fluorescence intensity was then evaluated
for 10,000 ungated cells on a FACSCAN flow cytometer.
3H-leucine uptake
Protein synthesis levels in target cells exposed to BsAb and
saporin were measured by 3H-leucine uptake. Triplicate cul-
tures of HSB-2 or HPB-ALL cells at a density of 1 x 105
cells per well in 96 well microculture plates were exposed for
48 h at 37°C to BsAb and saporin at each experimental
concentration. Each culture was then exposed for 12h to
1 ytCi 3H-leucine (TRK 510, Amersham International, Amer-
sham, UK) and finally harvested onto glassfibre filters using
a Skatron cell harvester. The amount of radioactive leucine
incorporated by cells was measured by scintillation counting
the harvested cells on the glassfibre discs in a Packard scintil-
lation counter. Results obtained for experimental cultures are
expressed as a percentage of the amount of 3H-leucine incor-
poration observed in untreated control cultures maintained
under identical conditions.
Kinetic studies
The kinetics of protein synthesis inactivation brought about
in HSB-2 cells by the anti-CD7 BsAb (HB2 x DB7-18) and
the anti-CD38 BsAb (OKT1O x RabSap) when used singly or
together in combination, was determined in 96 well microcul-
tures of cells exposed to various concentrations of saporin
(range 10-1 M to 10-0M). In these investigations the BsAb
HB2 x DB7- 18 was used at a concentration of 0.1 ygml-'
and the BsAb OKTlO x Rabsap at 1Lg ml-1. HSB-2 cells
were incubated for 2 h in supplemented leucine-free RPMI
medium at 37°C and then triplicate samples of 1 x 105 cells
added to wells of a 96 well microculture plate containing
each appropriate concentration of saporin and each BsAb
singly or in combination, in supplemented leucine-free
RPMI. Microculture plates were maintained at 37°C in a
humidified atmosphere of 5% CO2 in air and at 2, 6, 12, 24
and 48 h 1.0yCi 3H-leucine was added to each well of the
appropriate cultures and cells harvested after a 1 h pulse
exposure onto glassfibre mats as described above. Regression
analysis of 3H-leucine incorporation levels (expressed as a
percentage of untreated control cultures) versus each time-
point studied was undertaken for each saporin concentration
employed. The time taken to reduce the protein synthesis
level of HSB-2 cells by one log is defined as the t1o and was
obtained from the intercept point of the regression line with
the 10% level on the regression chart.
Results
Cell surface expression ofCD7 and CD38 by HSB-2 and
HPB-ALL
The expression of cell surface CD7 (MoAb HB2) and CD38
(MoAb OKT1O) by HSB-2 and HPB-ALL cells was deter-
Table 1 Specificities ofF(ab'7y)2 BsAbs used in this study
BsAb Specificities
HB2 x DB7-18 anti-CD7/anti-saporin (all monoclonal)a
OKT1O x DB7-18 anti-CD38/anti-saporin (all monoclonal)a
OKT1O x RabSap anti-CD38/anti-saporin (mono/polyclonal)b
aConstructed with two different monoclonal Fab' fragments.
bConstructed with one monoclonal Fab' fragment(OKTlO anti-CD38)
and rabbit anti-saporin Fab' fragments (RabSap).
mined by flow cytometry and the profiles obtained for each
cell line are shown in Figure 1. CD7 was expresssed strongly
by 98% of HSB-2 cells with a mean fluorescent intensity of
259 arbitrary units (Figure la). In contrast 90% of HPB-
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Figure 1 Flow cytometry profiles of CD7 and CD38 expression
by HSB-2 and HPB-ALL cells. Broken line indicates negative
control population, solid line indicates stained population.
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ALL cells were effectively negative for CD7 expression with a
subpopulation comprising approximately 10% of the total
expressing with a mean fluorescent intensity of 54 (Figure
lb). HSB-2 cells expressed CD38 only relatively weakly with
a mean fluorescent intensity for the whole population of only
eight arbitrary units (Figure Ic). HPB-ALL cells expressed
CD38 only moderately strongly with a mean fluorescent
intensity of 90 arbitrary units (Figure Id).
Titration ofeach BsAb singly or in combination against HSB-2
cells in thepresence ofsaporin
To determine the optimum concentration of antibody re-
quired to achieve maximal protein synthesis inhibition, each
BsAb was titrated against HSB-2 and HPB-ALL cells in the
presence of a sub-toxic concentration of saporin (0.1 jig
ml ' = 3.3 x 10-9 M). Protein synthesis levels were evaluated
after 48 h of continuous exposure and the results obtained
for this titration are shown in Figure 2. The CD7 BsAb
HB2 x DB7-18 performed best, achieving its IC50 at an
antibody concentration of 0.012 Ig ml-' whilst the CD38
BsAb OKTIO x RabSap constructed with rabbit polyclonal
anti-saporin Fab' fragments reached its IC50 at a concentra-
tion of 0.17ligml-'. The CD38 BsAb OKT1OxDB7-18
constructed with mouse monoclonal anti-saporin Fab' did
not inhibit protein synthesis in HSB-2 cells over the entire
range of BsAb concentrations investigated. Near maximal
protein synthesis inactivation in HSB-2 cells occurred at
BsAb concentrations of 0.1ILg ml-' for HB2 x DB7-18 and
1 jig ml-' for OKT1O x RabSap. The same optimal concen-
trations of BsAb were also demonstrated for the HPB-ALL
cell line in identical experiments (data not shown). On the
basis of these titration results obtained for single BsAb we
elected to employ HB2 x DB7-18 at 0.1ILg ml-' and OKT-
10 x RabSap at 1 jlgml1' throughout these studies.
When a 1 to 10 ratio mixture of the CD7 and CD38 BsAb
HB2 x DB7-18 and OKTIO x RabSap was titrated against
HSB-2 cells, the combination of both BsAb performed better
than either BsAb used alone, the combination giving an IC50
of 0.008 jig ml-I (this value being an expression of the con-
centration of HB2 x DB7-18 BsAb in the mixture). Each
BsAb used in the absence of saporin over the range of
concentrations investigated had no significant effect on HSB-
2 protein synthesis levels (for the sake of graphical clarity
data for the BsAb HB2 x DB7-18 only is shown in Figure
2). Similarly, equimolar mixtures of pairs of relevant F(ab'")2
fragments from which each BsAb was constructed used over
the same concentration range, together with saporin at
0.1jIg ml-' (3.3 x 10-' M), had no significant effect on HSB-
2 protein synthesis levels (data for only HB2 + DB7-18 is
shown in Figure 2).
Titration ofsaporin against HSB-2 and HPB-ALL cells in the
presence ofsingle or combinations ofBsAb
Cultures of HSB-2 or HPB-ALL cells were exposed to
saporin alone ranging in concentration from 10-13 M to
10-6M or together with the CD7 BsAb HB2 x DB7-18
(0.1jIgml-'), the CD38 BsAb OKTO0 x RabSap (1 jg ml-')
or a combination of both BsAb together (0.1jIg ml-'
HB2 x DB7-18 + 1 jigml-' OKTIO x RabSap). HSB-2 and
HPB-ALL cells were also exposed to the monoclonal CD38
BsAb OKT10x DB7-18 (1ljg ml-') singly or in combina-
tion with the CD7 BsAb HB2 x DB7-18 together with
saporin over the range of saporin concentrations. Cells were
also exposed to saporin at the various concentrations
together with equivalent amounts of an eqimolar mixture of
pairs of the relevant F(ab'y)2 fragments from which each
BsAb was constructed. The protein synthesis levels, expressed
as a percentage of control levels, in cultures of cells con-
tinuously exposed for 48 h to each treatment are shown
graphically in Figures 3a (HSB-2 cells) and 3b (HPB-ALL
cells) and the IC50 and fold increase values summarised in
Table II.
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Figure 2 3H-leucine incorporation levels in HSB-2 cells exposed
tovariousconcentrationsoftheBsAb'sHB2 x DB7 -18(A A),
OKT10 x RabSap (0 *), a combination of both these
BsAb's together or to the BsAb OKT10 x DB7- 18 (O---0) in
the presence of saporin at 0.1ILgml-'. Levels are shown for
HSB-2 cells exposed to the BsAb HB2 x DB7-18 without
saporin (O---0). Bars indicate one standard deviation.
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Figure 3 3H-leucine incorporation levels in a, HSB-2 or b, HPB-
ALL cells exposed to various concentrations of saporin alone
(- U) or together with 0.1ILg ml-' HB2 x DB7-18 BsAb
(CD7) (A A), 1 ig ml-' OKTI0 x RabSap BsAb (CD38)
(0 *), a combination of both BsAb's together (CD7-
+ CD38) (V ---V) or an equimolar mixture of HB2 + DB7-18
F(ab'y)2 fragments ( ---0). Bars indicate one standard devia-
tion.
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Table 2 Inhibition of protein synthesis in HSB-2 and HPB-ALL cells by saporin
delivering bispecific antibodies used singly or in combination
aIC50 Fold increaseb
BsAb HSB-2 HPB-ALL HSB-2 HPB-ALL
HB2 x DB7- 18 0.23 nmol 5.00 nmol 435 8
(CD7)
OKT1O x RabSap 0.35 nmol 0.50 pmol 286 80,000
(CD38)
OKT1O x DB7- 18 5.00 nmol 2.00 nmol 20 20
(CD38)
HB2 x DB7-18
+ 0.025 nmol 0.80 pmol 4,000 50,000
OKT1O x RabSap
HB2 x DB7-18
+ 0.50 nmol 1.50 nmol 200 27
OKT1Ox DB7-18
Saporin only J 100.00 nmol 40.00 nmol
aIC50 calculated as the concentration of saporin needed to give 50% inhibition of
3H-leucine incorporation compared with untreatedcontrol cells. bFoldincreasecalculated
as IC50 saporin alone/IC50 of BsAb + saporin.
The results obtained for HSB-2 cells are shown in Figure
3a. The IC50 for saporin alone on HSB-2 cells was found to
be 100 nmol. The CD7 BsAb, HB2 x DB7-18 increased the
toxicity of saporin for HSB-2 cells 435-fold, decreasing the
IC50 to 0.23 nmol whilst the CD38 BsAb OKTI0 x RabSap
increased toxicity 286-fold with a decrease in the IC,o to
0.35 nmol. When both of these BsAb were used in combina-
tion an IC50 value of 0.025 nmol was obtained, this represen-
ting a 4,000-fold increase in saporin toxicity. Thus, both
BsAb used in combination exerted more than just an additive
effect. Neither pair of F(ab'y)2 fragments used together with
saporin at the various concentrations had any significant
influence on protein synthesis levels. For the sake of graph-
ical clarity only the curve for HB2 + DB7-18 F(ab'y)2 frag-
ments is shown in Figure 3a. Examination of the curves in
Figure 3a shows that at concentrations of saporin between
10-12 M and 10`0 M the CD38 BsAb OKT1O x RabSap per-
formed better than the CD7 BsAb HB2 x DB7-18, but per-
formance began to decline at concentrations of saporin above
10-10 M. In comparison the CD7 BsAb continued to perform
well up to 10-9 M, and outperformed the CD38 BsAb at
saporin concentrations above 1.5 x 010-M, the point at
which the two curves cross over on the graph (Figure 3a).
The monoclonal CD38 BsAb OKTIO x DB7-18 used at
Iglg ml-' performed poorly against HSB-2 cells giving an
IC50 of 5 nmol, this representing only a 20-fold increase in
saporin toxicity (Table 2).
The results obtained on HPB-ALL cells are shown in
Figure 3b. The IC50 for saporin alone was found to be
40 nmol, revealing this cell line to be two and a half times
more sensitive to saporin than HSB-2. The CD7 BsAb
HB2 x DB7-18 increased saporin toxicity only eight-fold
decreasing the IC50 to 5 nmol. The CD38 BsAb OKT-
10 x RabSap was highly effective, increasing saporin toxicity
80,000-fold with a reduction in the IC50 to 0.5 pmol. In
contrast the monoclonal CD38 BsAb OKTIO x DB7-18 per-
formed poorly against HPB-ALL cells giving an IC50 of
2 nmol this representing only a twenty-fold increase in sap-
orin toxicity (Table 2). Interestingly, when both the anti-CD7
BsAb HB2 x DB7-18 and anti-CD38 BsAb OKT-
10 x RabSap were used in combination against HPB-
-ALL cells, they were somewhat less effective than
OKTIO x RabSap used alone, the combination giving only a
50,000-fold increase in saporin toxicity compared with the
80,000-fold increase obtained for OKTIO x RabSap alone.
Kinetics ofprotein synthesis inactivation
Experiments were conducted to determine the rate at which
various concentrations of saporin inactivated protein syn-
thesis in HSB-2 cells in the presence ofeach BsAb used either
singly or in combination. In these experiments the concentra-
tion of BsAb was kept constant at 0.1 ig ml-' for
HB2 x DB7-18 or 1.0jigml-' for OKTIO x RabSap. The
rate slopes expressed as a percentage of the control level of
3H-leucine incorporation with respect to time, obtained for
HSB-2 cells treated with individual or a combination of both
BsAbs are shown in Figure 4. The rate of inactivation was
clearly shown to be concentration dependent and linear. The
time taken for 90% inhibition of protein synthesis relative to
an equivalent number of untreated control cells is defined as
the t,o and this value plotted against each concentration of
saporin used in the presence of each BsAb singly or in
combination is shown in Figure 5. Of the two BsAb, the
CD7 BsAb HB2 x DB7-18 clearly gave the most rapid rate
of protein synthesis inactivation for concentrations of saporin
between 10' M and 10-9 M. Interestingly, at a saporin con-
centration of 1010 M the CD38 BsAb OKTIO x RabSap
inactivated protein synthesis more rapidly with a t1o of 88 h
compared with 226 h for the CD7 BsAb. When the CD7 and
CD38 BsAb were used in combination the rate of protein
synthesis inactivation was substantially increased over the
entire range of saporin concentrations used (Figure 5). Thus,
at a saporin concentration of 10-10 M the t1o obtained for the
two BsAb used in combination was 48 h compared with 88 h
for the CD38 BsAb and 226 h for the CD7 BsAb when used
alone. At a saporin concentration of 10-" M the individual
CD7 and CD38 BsAb were both ineffective. In contrast the
combination of both BsAb together, with saporin at 1011 M
was effective giving a t,o value of 85 h.
Discussion
The studies described here have clearly demonstrated that the
effective cytotoxic dose of saporin that is delivered to HSB-2
cells is improved approximately ten-fold when targeted
against both CD7 and CD38 in comparison to either target
molecule alone. The CD7 BsAb HB2 x DB7-18 has proven
highly effective at selectively delivering saporin to HSB-2 cells
in this and previous studies (Flavell et al., 1991), there being
a clearly demonstrable dose response effect obtained when
either BsAb or saporin concentration are taken into account.
In the experiments described in the present paper, the CD38
BsAb OKTIO x RabSap, constructed with Fab' fragments
from a rabbit anti-saporin polyclonal antisera was also
effective at delivering a cytotoxic dose of saporin to HSB-2
cells and again there was a clearly demonstrable dose res-
ponse effect obtained when either BsAb or saporin concent-
ration were taken into consideration. The exquisite specificity
with which saporin is delivered to only the target cell via the
CD38 molecule has also been unequivocally demonstrated
for the BsAb OKT1O x RabSap. Thus, this BsAb fails to
deliver saporin to the CD38- cell line HL60 and moreover,
its ability to deliver a cytotoxic dose of saporin to HSB-2
cells is abrogated in the presence of a ten-fold excess of free
OKTIO (CD38) antibody (data not shown). In the context of
specificity we have also demonstrated that an irrelevant BsAbCYTOTOXICITY OF COMBINATIONS OF BSAB 549
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Figure 4 Kinetics ofprotein synthesis inactivation in HSB-2 cells
exposed to a range of saporin concentrations (10-" M to 10-' M)
together with a, HB2 x DB7- 18 0.1 fig ml- , b, OKTO0 x Rab-
Sap I fig ml- or c, a combination of both BsAb's used together.
Panel d, shows the inactivation rate in HSB-2 cells exposed to the
various concentrations of saporin alone. Regression coefficients
obtained at each saporin concentration for each treatment were
as follows: a, HB2 x DB7-18 (0.1 tog ml-') r = 0.983 (10-7M),
r = 0.999 (10-8 M), r = 0.992 (10-9 M), r = 0.567 (10-10 M),
r = 0.610 (10-" M b, OKTlO x RabSac (l Lg ml ') r = 0.957
(10-7 M), r = 0.932 (10-8 M), r = 0.953 (10-9 M), r = 0.907 (10-10
M), r = 0.094 (10-" M) c, HB2 x DB7-18 + OKTIO x RabSap
COMBINATION r = 0.984 (10-7 M), r = 0.955 (10-8 M),
r = 0.988 (10-9 M), r = 0.970 (10-'0 M), r = 0.982 (10 -" M).
RJD x DB7-18 with target cell specificity for an idiotypic
determinant on a mouse B-cell leukaemia cell line in one arm
and saporin in the other, had no influence on the protein
synthesis inhibitory effects of saporin on either HSB-2 or
HPB-ALL (data not shown).
On HSB-2 cells the CD38 BsAb OKTIO x RabSap gave an
Figure 5 Kinetics of protein synthesis inactivation in HSB-2
cells. The t1o values (time in hours to reduce protein synthesis
levels in treated cells to 10% of that seen in untreated control
cells) were obtained from the rate slopes shown in Figure 4
following exposure of HSB-2 cells to a range of saporin concen-
trations (10-l' M to 10' M), together with the BsAb HB2 x-
DB7-18 (O *), OKT1O x RabSap (A A) or a com-
bination of both BsAb's ( 0).
observed 286-fold increase in saporin toxicity compared
with the 435-fold increase observed for the CD7 BsAb
HB2 x DB7-18. The monoclonal CD38 BsAb OKT10-
x DB7-18 performed poorly on HSB-2 cells giving only a
twenty-fold increase in saporin toxicity.
When the BsAb HB2 x DB7-18 and OKT1O x RabSap
were used in combination against HSB-2 cells their
effectiveness was improved almost ten-fold compared with
the best BsAb, HB2 x DB7-18 used alone, the combination
giving a 4,000-fold increase in saporin toxicity. Thus, the
effect of both BsAb used in combination was more than just
additive and this probably reflects the fact that greater
numbers of toxin molecules gain entry to the cytosol with a
subsequent increase in the probability of achieving a hit on
target ribosomes. In the presence of the combination of BsAb
there is also the possibility of both derivatives binding to a
single saporin molecule due to the recognition of different
saporin epitopes. Such bivalent binding would allow cross
linking of adjacent CD7 and CD38 molecules on the target
cell surface and this may favour saporin internalisation and/
or availability. When a combination of the CD7 BsAb
HB2 x DB7-18 was used with the monoclonal CD38 BsAb
OKTIO x DB7-18 the mixture actually performed less well
than the CD7 BsAb alone. This can probably be accounted
for by a reduction in the amount of saporin available for
delivery to the target cell by the highly effective BsAb
HB2 x DB7-18 due to competition for free saporin by the
relatively ineffective BsAb OKTIO x DB7- 18.
In addition to an improved cytotoxicity, the combination
of BsAb also gave a substantially faster rate of protein
synthesis inactivation in HSB-2 cells. Similar increases in the
cytotoxic efficacy and rate of protein synthesis inactivation
have been reported for combinations of IT's for targeting
intact ricin against the CD2, CD5, CD7, and CD18 mole-
cules on the surface of the T-ALL cell line CEM (Strong et
al., 1985). It is our opinion that this increase may be
explained as a purely quantitative phenomenon and probably
does not represent a real increase in the rate of BsAb-saporin
internalisation or translocation from the endosome to cyto-
sol. Evidence in support of this contention comes from our
preliminary investigations which demonstrate that the modu-
lation rate for each BsAb is unaltered when the two BsAb
are used in combination (Morland, unpublished results). We
feel that it is much more likely that the higher concentration
of endosomal saporin achieved when this RIP is delivered to
two different molecules on the cell surface results in more
saporin gaining access to the cytosol per unit time simply
because more molecules are available for translocation. It is
currently not known whether saporin simultaneously targeted
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against both CD7 and CD38 on the same cell surface enters
the cell using a common endocytic vesicle or whether each
enters via a different route. Carriere et al. (1989) demon-
strated that internalization of a CD7 MoAb by the T-ALL
cell line CEM was via coated pits on the cell membrane. In
contrast internalisation of a CD5 MoAb rarely occurred via
these structures and for a CD4 MoAb it never occurred.
The CD38 BsAb OKT1O x RabSap constructed with rab-
bit polyclonal anti-saporin Fab' fragments was significantly
more potent against HPB-ALL than HSB-2 cells, giving an
80,000-fold increase in saporin toxicity (IC50 0.5 pmol). In
contrast the CD7 BsAb HB2 x DB7-18 performed poorly
against HPB-ALL giving only an eight-fold increase in tox-
icity. This poor performance probably reflects the low level
of expression of CD7 by HPB-ALL and the subsequent poor
delivery of saporin to the target cell surface. The combin-
ation of both HB2 x DB7-18 and OKTIO x RabSap per-
formed less well (IC50 0.8 pmol 50,000-fold) than
OKTIO x RabSap used alone (IC50 0.5 pmol 80,000-fold).
Again, this probably reflects competition for saporin by the
relatively ineffective (for HPB-ALL) BsAb HB2 x DB7-18,
thereby reducing the effective amount of saporin available for
delivery to the target cell by the highly potent BsAb
OKT1O x RabSap. This type of effect resulting in decreased
efficacy when one of the target molecules is expressed mini-
mally on the target cell would not occur with conventional
immunotoxins and we are currently conducting studies to
explore this matter further.
The poor performance of the monoclonal CD38 BsAb
OKTIO x DB7-18 (constructed with a monoclonal anti-
saporin Fab') when tested on either HSB-2 or HPB-ALL,
may indicate that cross linking of adjacent saporin molecules
bound at the target cell surface may be required for the
effective delivery of saporin to the cell interior via this partic-
ular cell surface molecule. Cross linking cannot be achieved
by the BsAb OKTIO x DB7-18 which recognises only a
single epitope on the saporin molecule and the failure of
OKTIO x DB7-18 may therefore be due to the inability of
this BsAb to cross link saporin molecules at the cell surface.
In contrast the BsAb OKTIO x RabSap constructed with
rabbit polyclonal anti-saporin Fab' fragments will recognise
more than one saporin epitope and is therefore capable of
cross linking adjacent saporin molecules at the cell surface.
In this context French et al. (1991) have demonstrated that a
BsAb constructed with a rabbit anti-saporin antiserum was
more effective for targeting saporin against the guinea pig
acute lymphoblastic leukaemia cell line L2C than BsAb con-
structed with a single monoclonal anti-saporin Fab arm.
Combinations of BsAb constructed with different anti-sapo-
rin monoclonal Fab' fragments recognising different epitopes,
performed considerably better than the single reagents alone.
These workers suggested that the increased effective antibody
affinity achieved for binding saporin to the target cell surface
via two different saporin epitopes might account for the
increased cytotoxicity.
One of the most important factors in determining the
effectiveness of any method employed for targeting drugs or
toxins to tumour cells remains the nature of the target
molecule and its level of expression on the tumour cell
surface. In order to be certain that drug or toxin is delivered
to each and every cell would require that the target molecule
be expressed ubiquitously by all cells within the tumour.
Tumour cells are by their very nature heterogeneous in many
respects, not least of all in their expression of cell surface
molecules. It is clear that should just a few tumour cells show
reduced or failed expression of the target molecule on the
membrane surface, then effective amounts of the therapeutic
agent would not be delivered and tumour regrowth would be
likely to occur from these escapee cells. Such has been shown
to be the case with the guinea pig acute lymphoblastic
leukaemia cell line L2C. Here Glennie et al. (1988) demon-
strated that the L2C tumour cell population re-emerging
following immunotherapy of tumour bearing animals with
saporin and a BsAb targeting against an idiotypic deter-
minant on the L2C cell surface in one Fab arm and saporin
in the other arm, were target antigen negative. It was
hypothesized that selective pressure put on the tumour cell
population allowed for the emergence of an antigen negative
subpopulation. Previous work of our own has shown that
HSB-2 cells escaping destruction, following in vitro treatment
with a BsAb targeting saporin against the CD7 molecule
expressed on the surface of this cell line, express CD7 at the
same level as untreated parent cells (Flavell et al., 1991). This
observation demonstrates that we have not selected for a
truly antigen negative population and we have concluded
that an epigenetic downregulation of CD7 by a minute sub-
population of HSB-2 cells allowed for their survival follow-
ing their initial treatment with BsAb and saporin. Upon
regrowth of the CD7- surviving population, CD7 expression
was upregulated once again. On the basis of these two
independent observations we are of the opinion that down-
regulation of target antigen expression due either to reversi-
ble epigenetic or an irreversible mutational event may both
on different occasions be independently responsible for target
cell escape.
In conclusion we have clearly demonstrated that targeting
saporin against both CD7 and CD38 on the leukaemia cell
surface increases cytotoxicity in more than just an additive
fashion and moreover increases the rate at which protein
synthesis is inactivated in the target cell. These findings are
likely to be of some importance in the clinical utility of such
therapeutic reagents in human leukaemia for a number of
reasons. Firstly, multiple antigen targeting should contribute
to overcoming problems encountered with single antigen
negative tumour cells present within the population which
would otherwise evade toxin delivery. Secondly, targeting
against more than one cell surface molecule delivers greater
quantities of saporin to those cells that express all target
molecules and leads to a more rapid and more effective
protein synthesis inactivation in the target cell. This is of
obvious importance where the in vitro serum half life of
BsAb or RIP is limited and where a more rapid rate of
intoxication would be of positive value. In vivo therapy
studies to investigate these matters employing severe com-
bined immune deficient (scid) mice bearing human leukaemia
xenografts are currently in progress.
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